INNATE PHARMA SA (IPHA): $4.10

0.24 (+6.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Innate Pharma SA (IPHA) Price Targets From Analysts

Use the tables below to see what analysts covering Innate Pharma SA think about its future price and what recommendations they have for investors and traders.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
6 $13 $4.74 $8.45 $4.24 99.29%

The Trend in the Analyst Price Target


Over the past 93 days, IPHA's average price target has gone down $6.54.

Over the past 193 days, IPHA's average upside potential has been 121.76%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2020-11-22 6 13.0 4.74 8.45 4.900 72.45%
2020-10-22 6 17.5 4.68 10.36 3.960 161.62%
2020-09-22 6 17.5 4.68 10.35 3.850 168.83%
2020-09-09 6 17.5 4.72 10.36 4.090 153.3%
2020-08-21 4 17.5 13.00 14.99 6.360 135.69%
2020-07-28 6 17.5 9.00 13.40 6.245 114.57%
2020-07-20 6 17.5 9.00 13.31 6.450 106.36%
2020-07-01 6 17.5 9.00 13.26 6.200 113.87%
2020-06-24 6 17.5 9.00 13.59 6.870 97.82%
2020-05-13 6 17.5 9.00 13.50 6.990 93.13%

IPHA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • The variance in analysts' estimates of IPHA is lower than 5.41% of all US stocks.
  • IPHA has a higher upside potential (average analyst target price relative to current price) than 85.25% of all US stocks.
  • Innate Pharma SA's average analyst price target is higher than 16.67% of all US stocks.
  • IPHA has a greater number of analysts covering the stock than 78.48% of stocks in the small market cap category.

Is IPHA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6958 seconds.